OMER Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Omeros Corp (OMER) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has positive catalysts such as hedge fund buying, bullish analyst ratings with a significant price target increase, and the recent FDA approval of Yartemlea, which is considered a critical inflection point for the company. While financial performance is weak, the long-term growth potential from Yartemlea and the low put-call ratios in options data suggest bullish sentiment. The technical indicators also show a bullish trend, making it a favorable entry point.
The MACD is positive and contracting, RSI is neutral at 41.523, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading near its pivot level of 11.66, with resistance at 12.092 and support at 11.229. Overall, the technical indicators suggest a bullish trend.
FDA approval of Yartemlea for hematopoietic stem cell transplant-associated thrombotic microangiopathy, which is seen as a critical inflection point.
Hedge funds are heavily buying, with a 185085.19% increase in buying activity last quarter.
Analyst Brandon Folkes raised the price target to $40 from $20, citing the approval of Yartemlea as a major driver.
Weak financial performance in Q3 2025, with net income dropping to -$30.92M and EPS declining by -16.07% YoY.
No recent news or congress trading data to provide additional support for the stock.
In Q3 2025, revenue remained at $0 with no growth, net income dropped to -$30.92M (-4.08% YoY), and EPS declined to -0.47 (-16.07% YoY). Gross margin was 0, showing no improvement.
Analyst Brandon Folkes from H.C. Wainwright raised the price target to $40 from $20 and reiterated a Buy rating, citing the FDA approval of Yartemlea as a critical growth driver and validation of the company's value.
